Mutant p53 and sIL-1Ra
نویسندگان
چکیده
منابع مشابه
Mutant p53 and sIL-1Ra
microenvironment of solid tumors is composed of malignant cells surrounded by a reactive stroma containing extracellular matrix with a huge infiltration of non-malignant populations (myeloid cells, lymphocytes, fibroblast, endothelial cells), which together with several cytokines/chemokines, tissue remodelling and angiogenesis support an inflammatory milieu. Tumor growth and metastasis are the ...
متن کاملChromatin dysregulation by mutant p53
The TP53 gene, which encodes a DNA sequencedependent transcriptional regulator, is arguably the most frequently mutated gene in human cancer. Whereas wildtype p53 is restricted to its cognate DNA binding sites, mutant p53 (via mutation in the DNA binding domain) is no longer constrained to specific genomic sites. Mutant p53 proteins therefore cannot effectively mediate wildtype p53 tumor suppre...
متن کاملMutant p53 succumbs to starvation
While the wild type form of p53 possesses strong tumor-suppressive activities, the p53 proteins that are commonly mutated in cancer often endow more malignant properties to the cancers they inhabit. There are several lines of evidence supporting such oncogenic gain of function of mutant p53. Compared with p53-null mice, knock-in mice harboring mutant p53 proteins display different and more meta...
متن کاملAllele-specific p53 mutant reactivation.
Rescuing the function of mutant p53 protein is an attractive cancer therapeutic strategy. Using the National Cancer Institute's anticancer drug screen data, we identified two compounds from the thiosemicarbazone family that manifest increased growth inhibitory activity in mutant p53 cells, particularly for the p53(R175) mutant. Mechanistic studies reveal that NSC319726 restores WT structure and...
متن کاملThe SLC25A1-p53 mutant crosstalk
presence of p53 mutations in human cancers, which occurs with a frequency higher than 50%, is a negative prognostic factor predictive of relapse and of resistance to chemo-and radio-therapy, thus rendering these types of tumors a still unsolved therapeutic challenge. While various compounds have become available for the treatment of tumors expressing other types of "driver" oncogenic mutations,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Aging
سال: 2015
ISSN: 1945-4589
DOI: 10.18632/aging.100825